The pharmaceutical business is still working toward independence and health security due to the changes in the market brought on by the pandemic circumstances, the global financial crisis, and the high US Dollar exchange rate against the Rupiah. Dexa Group presented three significant initiatives for pharmaceutical resilience and independence with government assistance.
“The nation has to develop resilience and self-sufficiency since its reliance on imports causes it to tremble. Direct manufacturing costs are high when the value of the US Dollar increases. Based on directives from President Joko Widodo, which were carried out by the Ministry of Health and the POM, this is a commendable move,” Chairman of PT Dexa Medica V. Hery Sutanto made the statement on November 4, 2022, during the National Health Day Exhibition.
The Dexa Group has made three significant contributions to the tenacity and autonomy of Indonesian medicines. The first is autonomy in Indonesian Indigenous Modern Medicine (IIMM), often known as autonomy in contemporary herbal remedies.
“Secondly, through Dexa’s sister company, Ferron Par Pharmaceuticals, it also produces raw materials for the chemical synthesis of Omeprazole and Esomeprazole. Third, we also use Obat Generik Berlogo (OGB), whose raw materials are from Kimia Farma Sungwun Parmacopia, for which we signed the MoU yesterday. We need to support this government program. We buy (domestic drug raw materials) for us to market,” explained Mr. V. Hery.
Towards the Glory of Indonesia Indigenous Modern Medicine Phytopharmaceutical
Director of Research and Business Development Dexa Group Prof. Dr. Raymond Tjandrawinata was a speaker in the talk show entitled “Towards the Glory of Indigenous Indonesian Modern Medicine” at the 58th National Health Day on Friday, 4 November 2022.
As one of the strategic efforts related to independence in Indigenous Indonesian Modern Medicine (OMAI) Fitofarmaka, Prof. Dr. Raymond said that Dexa Group had produced Modern Original Indonesian Medicines with high TKDN. They start with raw materials, raw material producers, and researchers, and the research, development, and distribution processes come from Indonesia.
Dexa Group has produced 63% of OMAI phytopharmaceutical products from 57 phytopharmaceutical items registered in the POM Agency’s Marketing Permit Number (NIE). Meanwhile, Standardized Herbal Medicines (OHT) produced by Dexa Group reached 26% of the 125 NIE of the POM Agency.
Dexa Group has 57 phytopharmaceutical goods registered in the BPOM Marketing Permit Number, producing 63% of IIMM phytopharmaceutical products. Meanwhile, Dexa Group’s Standardized Herbal Medicines (OHT) attained 26% of the 125 NIE of the POM Agency.
“We appreciate the support and steps that the government has taken, especially the Ministry of Health, the POM Agency, and the Ministry of Industry, for the development of IIMM through several policies, including the Phytopharmaceutical Formulary that has been launched, the use of domestic products through e-catalogs, the construction of research facilities and industrial infrastructure to ease the acceleration of licensing. This is a tangible manifestation of the seriousness of the government and industry players in encouraging the use of OMAI. It is hoped that this commitment will be accompanied by the contribution and support of the community in choosing domestic products for national health resilience and independence,” said Prof. Raymond.
People shouldn’t think twice about voting for IIMM, according to Professor Raymond Tjandrawinata. This is because Dexa Medica’s products utilize evidence-based medicine.
Most phytopharmaceuticals are prescribed by doctors using the Ministry of Health’s Phytopharmaceutical Formulary. Doctors are confident that Dexa Medica’s evidence-based medication works because, although being herbal, it is handled in a contemporary manner. “We undertake clinical testing, and it is trustworthy that this medication has excellent qualities,” according to Prof. Raymond.
Prof. Raymond explained that Dexa Group’s seriousness in building independence through IIMM could be proven, one of which is the clinical trial process for Fitofarmaka products. “Each product has different clinical trials; for example, Inaclin has eight stages of clinical trials, and each stage takes an average of 2 years, which means eight times two years. The more we add data, the more convinced doctors will be to use this drug,” explained Prof. Raymond.
Because it has evidence-based medicine, Dexa Group’s IIMM products have penetrated the export market. Several countries on four continents in Africa, America, Asia, and Europe have become markets for IIMM products.
Dexa Group’s Phytopharmaceutical products that have been registered in the Phytopharmaceutical Formulary are Stimuno (immunomodulator), Inlacin (antidiabetic), Redacid (to treat gastric ulcers) and Disolf (blood circulation promoter). Because of this IIMM Fitofarmaka product, Dexa Medica won an award from the Indonesian Ministry of Health as the Most Phytopharmaceutical Producer at the 2022 National Health Day event.